Cryo Cell International Inc: Form 10-Q for the period ended May 31, 2012
Filed with the SEC on Jul 16, 2012 and accepted by EDGAR at Jul 16, 2012, 21:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-05-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-03-01 to 2012-05-31 | $4.4m | us-gaap:Revenues |
| Revenue | 6 months2011-12-01 to 2012-05-31 | $8.6m | us-gaap:Revenues |
| Cost of revenue | 3 months2012-03-01 to 2012-05-31 | $1.2m | us-gaap:CostOfServices |
| Cost of revenue | 6 months2011-12-01 to 2012-05-31 | $2.2m | us-gaap:CostOfServices |
| Research and development | 3 months2012-03-01 to 2012-05-31 | $7.8k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2011-12-01 to 2012-05-31 | $22.4k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2012-03-01 to 2012-05-31 | $4.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2011-12-01 to 2012-05-31 | $7.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2012-03-01 to 2012-05-31 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2011-12-01 to 2012-05-31 | −$1.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2012-03-01 to 2012-05-31 | $277.3k | us-gaap:InterestExpense |
| Interest expense | 6 months2011-12-01 to 2012-05-31 | $576.4k | us-gaap:InterestExpense |
| Income tax | 3 months2012-03-01 to 2012-05-31 | $1.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2011-12-01 to 2012-05-31 | $1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2012-03-01 to 2012-05-31 | −$3.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2011-12-01 to 2012-05-31 | −$4.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2012-03-01 to 2012-05-31 | −$0.28 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2011-12-01 to 2012-05-31 | −$0.43 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2012-03-01 to 2012-05-31 | −$0.28 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2011-12-01 to 2012-05-31 | −$0.43 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2012-03-01 to 2012-05-31 | 11,322,143 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2011-12-01 to 2012-05-31 | 11,405,106 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2011-12-01 to 2012-05-31 | −$385.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2011-12-01 to 2012-05-31 | $116.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2011-12-01 to 2012-05-31 | $1.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2012-05-31 | $2.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-05-31 | $9.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2012-05-31 | $13.1m | us-gaap:Assets |
| Current liabilities | At period end2012-05-31 | $9.8m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2012-05-31 | $2.6m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2012-05-31 | −$7.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001193125-12-303575. Last ingested by Listed: Oct 24, 2026, 14:58 ET. Listed shows no prices and gives no investment advice.